Horus Pharma and NovaMedica Sign Agreement to Market a Portfolio of Eye Care Products in Russia

Print 02 October 2014
MarketWatch

MOSCOW & SAINT-LAURENT-DU-VAR, France, Sep 30, 2014 (BUSINESS WIRE) -- NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).

Products include: hylaluronic acid containing ILast to assist healing of the eyelids following surgery; easy to swallow Macula-Z-Oro combining essential vitamins for eye health Antiseptic; and single dose and preservative-free Vitamine B12 eye drops to promote healing.

The first sales from this portfolio of products are expected in 2015, and NovaMedica will have the option to commercialize future Horus Pharma products currently under development with special focus on Glaucoma treatment.

“With a sizeable and continually expanding commercial portfolio from Clearside Biomedical, ReVision Optics, SiFi, and now Horus Pharma, NovaMedica will deliver a unique and innovative combination of products and technologies to the Russian ophthalmic market,” said Fabrice Egros, Chief Operating Officer of NovaMedica. “This will enable Russian eye care doctors to address a wide variety of ophthalmic problems and bring substantial benefits to Russian patients.”

Horus Pharma CEO Claude Claret also welcomes this new international partnership which opens up new pharmaceutical perspectives in Russia.

“NovaMedica is a team of professionals with deep and thorough expertise of the Russian biotech market — an ideal partner capable of registering and effectively marketing our products. We are delighted to be able to tap demand from the rapidly growing ophthalmology market in Russia and other CIS countries,” said Claude Claret. “This agreement also offers an opportunity for further business activities and, undoubtedly, it will contribute to a broader availability of advanced therapies to Russian patients.”

Source

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news